Monday, February 26, 2024
At this meeting, we will present "Losing Fat Mass without Impacting Muscle Mass: A New Approach for Weight Loss". Ridgeline is developing transformative oral drugs for the multi-billion obesity and muscle regeneration markets. Our robust pipeline is advancing drugs that modulate cellular metabolic pathways recently identified as underlying the pathophysiology of obesity, Type 2 diabetes, sarcopenia (age-linked muscle weakness), and muscle repair. In the obesity space, our drugs reduce excess fat tissue and reverse obesity comorbid diseases (e.g., fatty liver, Type 2 diabetes). Unlike GLP-1 mimics, they MAINTAIN muscle mass and do NOT decrease food intake. In the muscle regeneration space, our drugs increase muscle mass and strength in older populations and speed the repair and rebuilding of muscle mass and strength following muscle or joint injury. We are on track for clinical trials to begin in 2024.
CEO/Top Company Official
Lead Product in Development
RT-002 is a clinical candidate for IND submission package.
Development Phase of Primary Product
Number Of Unlicensed Products